<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>ONVO - News and Analysis from Seeking Alpha</title>
    <description>'ONVO' Tag RSS Syndication from SeekingAlpha.com</description>
    <author>
      <name>SeekingAlpha.com</name>
    </author>
    <link>http://seekingalpha.com/symbol/onvo</link>
    <item>
      <title>Organovo Holdings: So Much Potential</title>
      <link>http://seekingalpha.com/article/751371-organovo-holdings-so-much-potential?source=feed</link>
      <guid isPermaLink="false">751371</guid>
      <content>
        <![CDATA[<p>3D printing has been heralded by some as the future of manufacturing and the breakthrough that will take us into a new productivity boom. The idea of using computers and robotics to assemble items from scratch is a growing trend and one company has decided to embrace the concept with an organic twist.</p> <p>Organovo Holdings (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>) is a revolutionary company that uses 3D printing technology to build organic tissues one cell at a time. The potential applications for this technology are simply astounding with the possibility of replacement organ and tissue manufacturing that would revolutionize medicine and the healthcare industry. With an innovative management team and a potentially lucrative patent portfolio, it would seem that the sky is the limit for ONVO.</p> <p>
  <strong>Trees Growing to the Sky</strong>
</p> <p>That would be the mindset that drove ONVO from an opening IPO price of 1.65 to a nosebleed peak of 10.90 in just</p>]]>
      </content>
      <pubDate>Thu, 26 Jul 2012 09:45:59 -0400</pubDate>
      <author>Josh Krause</author>
      <description>
        <![CDATA[- <strong>By <a href='http://cms.seekingalpha.com/author/josh-krause/'>Josh Krause</a>:</strong><p>3D printing has been heralded by some as the future of manufacturing and the breakthrough that will take us into a new productivity boom. The idea of using computers and robotics to assemble items from scratch is a growing trend and one company has decided to embrace the concept with an organic twist.</p> <p>Organovo Holdings (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>) is a revolutionary company that uses 3D printing technology to build organic tissues one cell at a time. The potential applications for this technology are simply astounding with the possibility of replacement organ and tissue manufacturing that would revolutionize medicine and the healthcare industry. With an innovative management team and a potentially lucrative patent portfolio, it would seem that the sky is the limit for ONVO.</p> <p>
  <strong>Trees Growing to the Sky</strong>
</p> <p>That would be the mindset that drove ONVO from an opening IPO price of 1.65 to a nosebleed peak of 10.90 in just</p><br/><a href='http://seekingalpha.com/article/751371-organovo-holdings-so-much-potential?source=feed'>Complete Story &raquo;</a>]]>
      </description>
      <category type="symbol" link="http://seekingalpha.com/symbol/ddd">DDD</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/onvo">ONVO</category>
      <category type="author" link="http://seekingalpha.com/author/josh-krause">Josh Krause</category>
    </item>
    <item>
      <title>The Lowdown On Organovo Holdings</title>
      <link>http://seekingalpha.com/article/718561-the-lowdown-on-organovo-holdings?source=feed</link>
      <guid isPermaLink="false">718561</guid>
      <content>
        <![CDATA[<p>If any of you have been following 3-D Printing Technology stocks, then you should have at least heard of Organovo Holdings, Inc (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>). According to the business summary Yahoo Finance provides:</p><blockquote class="quote">
  <p>Organovo Holdings, Inc. develops NovoGen three-dimensional (3D) human tissue printing technology for creating tissue on demand for research and surgical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. serves physicians and researchers involved in the fields of cardiovascular medicine, medical research, and transplant medicine.</p>
</blockquote><p>This company has been wildly popular. Their co-founder was featured in "<a href="http://www.fastcompany.com/100/2010/80/gabor-forgacs/" rel="nofollow">The 100 Most Creative People in Business 2010</a>." They have also seen <a href="http://investors.organovo.com/Newsroom/Media-Coverage/default.aspx" rel="nofollow">media attention</a> through the popular <em>Wired</em> magazine, <em>Time</em> magazine, he <em>Wall Street Daily</em>, and <em>Bloomberg Businessweek</em>. They were even <a href="http://investors.organovo.com/Newsroom/Press-Releases/Press-Releases-Details/2012/Organovo-Named-to-MIT-Technology-Reviews-2012-TR50-List-of-the-Worlds-Most-Innovative-Companies1128426/default.aspx" rel="nofollow">named to</a> "MIT Technology Review's 2012 TR50 List of the World's Most Innovative Company."</p><p>
  <b>Is it a Pump-and-Dump Scheme?</b>
</p><p>In short:</p>]]>
      </content>
      <pubDate>Thu, 12 Jul 2012 17:33:57 -0400</pubDate>
      <author>Brandon Hall</author>
      <description>
        <![CDATA[<strong>By <a href='http://thewitlessinvestor.wordpress.com/'>Brandon Hall</a>:</strong><p>If any of you have been following 3-D Printing Technology stocks, then you should have at least heard of Organovo Holdings, Inc (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>). According to the business summary Yahoo Finance provides:</p><blockquote class="quote">
  <p>Organovo Holdings, Inc. develops NovoGen three-dimensional (3D) human tissue printing technology for creating tissue on demand for research and surgical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. serves physicians and researchers involved in the fields of cardiovascular medicine, medical research, and transplant medicine.</p>
</blockquote><p>This company has been wildly popular. Their co-founder was featured in "<a href="http://www.fastcompany.com/100/2010/80/gabor-forgacs/" rel="nofollow">The 100 Most Creative People in Business 2010</a>." They have also seen <a href="http://investors.organovo.com/Newsroom/Media-Coverage/default.aspx" rel="nofollow">media attention</a> through the popular <em>Wired</em> magazine, <em>Time</em> magazine, he <em>Wall Street Daily</em>, and <em>Bloomberg Businessweek</em>. They were even <a href="http://investors.organovo.com/Newsroom/Press-Releases/Press-Releases-Details/2012/Organovo-Named-to-MIT-Technology-Reviews-2012-TR50-List-of-the-Worlds-Most-Innovative-Companies1128426/default.aspx" rel="nofollow">named to</a> "MIT Technology Review's 2012 TR50 List of the World's Most Innovative Company."</p><p>
  <b>Is it a Pump-and-Dump Scheme?</b>
</p><p>In short:</p><br/><a href='http://seekingalpha.com/article/718561-the-lowdown-on-organovo-holdings?source=feed'>Complete Story &raquo;</a>]]>
      </description>
      <category type="symbol" link="http://seekingalpha.com/symbol/onvo">ONVO</category>
      <category type="author" link="http://seekingalpha.com/author/brandon-hall">Brandon Hall</category>
    </item>
    <item>
      <title>Organovo Shares Could Be Headed To $3 Per Share</title>
      <link>http://seekingalpha.com/article/687621-organovo-shares-could-be-headed-to-3-per-share?source=feed</link>
      <guid isPermaLink="false">687621</guid>
      <content>
        <![CDATA[<p>
  <em>Note: This article has been corrected to reflect that the date for lockup expiration is unknown. </em>
</p><p><strong>Organovo Holdings (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>)</strong> was added to our <a href="http://blog.geoinvesting.com/?page_id=2801" rel="nofollow">speculative screen</a> on February 28th 2012 at $1.65. We stated:</p><ul>
  <li>ONVO Just completed a reverse merger with a company focused on the development of bio-printing technology for research and medical applications.</li>
  <li>Concurrent with its reverse merge, the company was able to raise $6.5 million.</li>
  <li>ONVO was beginning to attend investor conferences.</li>
</ul><p>On June 25, 2012, we alerted our Premium members that we were taking a short position in ONVO shares.</p><p>
  <strong>Look Out Below</strong>
</p><p>Since February 28, 2012 ONVO has skyrocketed, reaching a high of $10.90 on June 18, 2012. We see little fundamental reason to explain why the stock has made such an aggressive move. But we believe that shares could get destroyed once an <a href="http://sec.gov/Archives/edgar/data/1497253/000119312512269648/0001193125-12-269648-index.htm" rel="nofollow">S-1 filed on June 13, 2012</a> goes effective. This will allow investors</p>]]>
      </content>
      <pubDate>Wed, 27 Jun 2012 12:09:47 -0400</pubDate>
      <author>The GeoTeam</author>
      <description>
        <![CDATA[<p>
  <em>Note: This article has been corrected to reflect that the date for lockup expiration is unknown. </em>
</p><p><strong>Organovo Holdings (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>)</strong> was added to our <a href="http://blog.geoinvesting.com/?page_id=2801" rel="nofollow">speculative screen</a> on February 28th 2012 at $1.65. We stated:</p><ul>
  <li>ONVO Just completed a reverse merger with a company focused on the development of bio-printing technology for research and medical applications.</li>
  <li>Concurrent with its reverse merge, the company was able to raise $6.5 million.</li>
  <li>ONVO was beginning to attend investor conferences.</li>
</ul><p>On June 25, 2012, we alerted our Premium members that we were taking a short position in ONVO shares.</p><p>
  <strong>Look Out Below</strong>
</p><p>Since February 28, 2012 ONVO has skyrocketed, reaching a high of $10.90 on June 18, 2012. We see little fundamental reason to explain why the stock has made such an aggressive move. But we believe that shares could get destroyed once an <a href="http://sec.gov/Archives/edgar/data/1497253/000119312512269648/0001193125-12-269648-index.htm" rel="nofollow">S-1 filed on June 13, 2012</a> goes effective. This will allow investors</p><br/><a href='http://seekingalpha.com/article/687621-organovo-shares-could-be-headed-to-3-per-share?source=feed'>Complete Story &raquo;</a>]]>
      </description>
      <category type="symbol" link="http://seekingalpha.com/symbol/ddd">DDD</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/pfe">PFE</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/ssys">SSYS</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/uthr">UTHR</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/onvo">ONVO</category>
      <category type="author" link="http://seekingalpha.com/author/the-geoteam">The GeoTeam</category>
    </item>
    <item>
      <title>The 3-D Printing Revolution Is Underway - 2 Companies With Dominant Market Share, Rapid Growth Potential</title>
      <link>http://seekingalpha.com/article/631791-the-3-d-printing-revolution-is-underway-2-companies-with-dominant-market-share-rapid-growth-potential?source=feed</link>
      <guid isPermaLink="false">631791</guid>
      <content>
        <![CDATA[<p>3D printing is a rapidly growing technology sector that is still in its infancy. The ability to create highly detailed custom works at a fraction of the price is bringing waves of retail investors into these stocks. 3D printing is expected to replace many hands-on jobs as less human involvement is needed in manufacturing. Stratasys (<a href='http://seekingalpha.com/symbol/ssys' title='Stratasys, Inc.'>SSYS</a>) and 3D Systems (<a href='http://seekingalpha.com/symbol/ddd' title='3D Systems Corp.'>DDD</a>) are at the forefront of monetizing their 3D printers; both companies have recently announced their new product line of affordable 3D printers for the general public.</p><p>What does <a href="http://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=Logarithmic&amp;chdeh=1&amp;chfdeh=0&amp;chdet=1337284800000&amp;chddm=234600&amp;chddi=604800&amp;chls=Ohlc&amp;q=NASDAQ:SSYS&amp;ntsp=0" rel="nofollow">Stratasys</a> do?</p><blockquote class="quote">
  <p>Stratasys, Inc. is a manufacturer of three-dimensional 3D printers and 3D production systems for the office-based rapid prototyping (<a href='http://seekingalpha.com/symbol/rp' title='RealPage'>RP</a>) and direct digital manufacturing (<a href='http://seekingalpha.com/symbol/ddm' title='ProShares Ultra Dow 30 ETF'>DDM</a>) markets. The Company develops, manufactures and sells a product line of 3D printers and RP systems (and related consumable materials) that create physical parts from computer-aided design (<a href='http://seekingalpha.com/symbol/cad' title='PIMCO Canada Bond Index ETF'>CAD</a>) designs. It also offers rapid prototyping and production</p></blockquote>]]>
      </content>
      <pubDate>Fri, 01 Jun 2012 14:45:59 -0400</pubDate>
      <author>Andrew Bowden</author>
      <description>
        <![CDATA[<strong>By <a href='http://seekingalpha.com/author/andrew-bowden/'>Andrew Bowden</a>:</strong><p>3D printing is a rapidly growing technology sector that is still in its infancy. The ability to create highly detailed custom works at a fraction of the price is bringing waves of retail investors into these stocks. 3D printing is expected to replace many hands-on jobs as less human involvement is needed in manufacturing. Stratasys (<a href='http://seekingalpha.com/symbol/ssys' title='Stratasys, Inc.'>SSYS</a>) and 3D Systems (<a href='http://seekingalpha.com/symbol/ddd' title='3D Systems Corp.'>DDD</a>) are at the forefront of monetizing their 3D printers; both companies have recently announced their new product line of affordable 3D printers for the general public.</p><p>What does <a href="http://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=Logarithmic&amp;chdeh=1&amp;chfdeh=0&amp;chdet=1337284800000&amp;chddm=234600&amp;chddi=604800&amp;chls=Ohlc&amp;q=NASDAQ:SSYS&amp;ntsp=0" rel="nofollow">Stratasys</a> do?</p><blockquote class="quote">
  <p>Stratasys, Inc. is a manufacturer of three-dimensional 3D printers and 3D production systems for the office-based rapid prototyping (<a href='http://seekingalpha.com/symbol/rp' title='RealPage'>RP</a>) and direct digital manufacturing (<a href='http://seekingalpha.com/symbol/ddm' title='ProShares Ultra Dow 30 ETF'>DDM</a>) markets. The Company develops, manufactures and sells a product line of 3D printers and RP systems (and related consumable materials) that create physical parts from computer-aided design (<a href='http://seekingalpha.com/symbol/cad' title='PIMCO Canada Bond Index ETF'>CAD</a>) designs. It also offers rapid prototyping and production</p></blockquote><br/><a href='http://seekingalpha.com/article/631791-the-3-d-printing-revolution-is-underway-2-companies-with-dominant-market-share-rapid-growth-potential?source=feed'>Complete Story &raquo;</a>]]>
      </description>
      <category type="symbol" link="http://seekingalpha.com/symbol/ddd">DDD</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/onvo">ONVO</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/ssys">SSYS</category>
      <category type="author" link="http://seekingalpha.com/author/andrew-bowden">Andrew Bowden</category>
    </item>
    <item>
      <title>Organovo's 3D Bioprinting: A Win For Pharmaceuticals?</title>
      <link>http://seekingalpha.com/article/428421-organovo-s-3d-bioprinting-a-win-for-pharmaceuticals?source=feed</link>
      <guid isPermaLink="false">428421</guid>
      <content>
        <![CDATA[<p>    <em>By Ryan Fitzwater </em></p> <p>What you’re about to read could change the world of medicine as we know it.</p>  <p>The technology I’m talking about is three-dimensional cellular construction, better known as 3D bioprinting, and the company delivering this revolutionary technology is <strong>Organovo</strong> (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>).</p> <p>Based in San Diego, and founded in 2007, Organovo is a startup that looks to take regenerative medicine to the next level with its bioprinting technology.</p> <p>
  <strong>How It Works</strong>
</p> <p>Organovo has created the NovoGen MMX Bioprinter™, the only commercial bioprinter in the world proven to create tissue.</p> <p>
  <iframe src="http://www.youtube.com/embed/1O3c3pUg0L8" width="460" height="335" frameborder="0"/>
</p> <p>Using both a software and hardware platform, NovoGen can take primary or other human cells and form them into three-dimensional tissue.</p> <p>You might have heard of companies who are already in the <a href="http://www.investmentu.com/2011/June/3d-printing.html" rel="nofollow">3D printing industry</a> like <strong>Stratasys</strong> (Nasdaq: <a href='http://seekingalpha.com/symbol/ssys' title='Stratasys, Inc.'>SSYS</a>) or <strong>3D Systems</strong> (NYSE: <a href='http://seekingalpha.com/symbol/ddd' title='3D Systems Corp.'>DDD</a>), which can scan and make objects out of various materials. But what separates Organovo printers from others</p>]]>
      </content>
      <pubDate>Mon, 12 Mar 2012 16:35:31 -0400</pubDate>
      <author>Investment U</author>
      <description>
        <![CDATA[
<strong>By <a href='http://www.investmentu.com/'>Investment U</a>: </strong><p>    <em>By Ryan Fitzwater </em></p> <p>What you’re about to read could change the world of medicine as we know it.</p>  <p>The technology I’m talking about is three-dimensional cellular construction, better known as 3D bioprinting, and the company delivering this revolutionary technology is <strong>Organovo</strong> (<a href='http://seekingalpha.com/symbol/onvo' title='Organovo Holdings, Inc.'>ONVO</a>).</p> <p>Based in San Diego, and founded in 2007, Organovo is a startup that looks to take regenerative medicine to the next level with its bioprinting technology.</p> <p>
  <strong>How It Works</strong>
</p> <p>Organovo has created the NovoGen MMX Bioprinter™, the only commercial bioprinter in the world proven to create tissue.</p> <p>
  <iframe src="http://www.youtube.com/embed/1O3c3pUg0L8" width="460" height="335" frameborder="0"/>
</p> <p>Using both a software and hardware platform, NovoGen can take primary or other human cells and form them into three-dimensional tissue.</p> <p>You might have heard of companies who are already in the <a href="http://www.investmentu.com/2011/June/3d-printing.html" rel="nofollow">3D printing industry</a> like <strong>Stratasys</strong> (Nasdaq: <a href='http://seekingalpha.com/symbol/ssys' title='Stratasys, Inc.'>SSYS</a>) or <strong>3D Systems</strong> (NYSE: <a href='http://seekingalpha.com/symbol/ddd' title='3D Systems Corp.'>DDD</a>), which can scan and make objects out of various materials. But what separates Organovo printers from others</p><br/><a href='http://seekingalpha.com/article/428421-organovo-s-3d-bioprinting-a-win-for-pharmaceuticals?source=feed'>Complete Story &raquo;</a>]]>
      </description>
      <category type="symbol" link="http://seekingalpha.com/symbol/ddd">DDD</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/ssys">SSYS</category>
      <category type="symbol" link="http://seekingalpha.com/symbol/onvo">ONVO</category>
      <category type="author" link="http://seekingalpha.com/author/investment-u">Investment U</category>
    </item>
  </channel>
</rss>
